GlassScriptPhysician profile
Lester A Crancer, III
NPI 1285682864
$1,027.31
in general payments reported to CMS, 2019-2025
20 companies · $218 in 2025
The $218 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $15.16 · 2020: $17.93 · 2021: $340 · 2022: $104 · 2023: $164 · 2024: $167 · 2025: $218.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $550.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $550.04 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $433.94 | 2021-2023 | Vraylar |
| Pfizer INC. | $77.89 | 2024-2025 | |
| Astrazeneca Pharmaceuticals LP | $70.20 | 2022-2025 | Breztri, Farxiga, Airsupra |
| Glaxosmithkline, LLC. | $46.93 | 2025 | Trelegy Ellipta |
| Astellas Pharma US INC | $41.96 | 2022-2024 | Veozah |
| Lundbeck LLC | $41.77 | 2024-2025 | Rexulti |
| Lilly USA, LLC | $38.93 | 2021-2022 | |
| Medtronic, INC. | $38.82 | 2023 | Intellis Adaptivestim |
| Teva Pharmaceuticals USA, INC. | $28.69 | 2023-2025 | Austedo Xr, Austedo Xr |
| Neurocrine Biosciences, INC. | $24.86 | 2025 | |
| Novartis Pharmaceuticals Corporation | $22.81 | 2023 | |
| Sanofi-Aventis U.S. LLC | $22.30 | 2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $20.98 | 2025 | Jardiance |
| Aimmune Therapeutics, INC. | $19.43 | 2024 | |
| Merck Sharp & Dohme LLC | $19.10 | 2022 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $17.93 | 2020 | |
| Radius Health, INC. | $16.99 | 2025 | Tymlos |
| Inspire Medical Systems, INC. | $15.37 | 2024 | Inspire |
| Amarin Pharma, INC. | $15.16 | 2019 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $13.25 | 2024 | Caplyta |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lester Crancer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.